Shoichi Ohwada

809 total citations
20 papers, 447 citations indexed

About

Shoichi Ohwada is a scholar working on Oncology, Neurology and Physiology. According to data from OpenAlex, Shoichi Ohwada has authored 20 papers receiving a total of 447 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 8 papers in Neurology and 7 papers in Physiology. Recurrent topics in Shoichi Ohwada's work include Pain Mechanisms and Treatments (7 papers), Botulinum Toxin and Related Neurological Disorders (7 papers) and HER2/EGFR in Cancer Research (5 papers). Shoichi Ohwada is often cited by papers focused on Pain Mechanisms and Treatments (7 papers), Botulinum Toxin and Related Neurological Disorders (7 papers) and HER2/EGFR in Cancer Research (5 papers). Shoichi Ohwada collaborates with scholars based in Japan, Germany and United States. Shoichi Ohwada's co-authors include Masayuki Baba, Masanori Kuroha, Jitsu Kato, Masahiro Sugihara, Karen Brown, Victor Dishy, Satoshi Morita, Hiroshi Takatsuna, Kenichi Inoue and Takashi Shigekawa and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Pain.

In The Last Decade

Shoichi Ohwada

20 papers receiving 443 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Shoichi Ohwada Japan 14 220 181 157 87 66 20 447
Kiyonori Kai Japan 12 95 0.4× 168 0.9× 55 0.4× 143 1.6× 61 0.9× 38 493
Ching Hsu United States 10 130 0.6× 107 0.6× 84 0.5× 79 0.9× 11 0.2× 23 356
Tiffany Li Australia 15 89 0.4× 425 2.3× 106 0.7× 40 0.5× 17 0.3× 38 545
Marc Hattenberger Switzerland 7 208 0.9× 139 0.8× 23 0.1× 195 2.2× 27 0.4× 7 550
Hannah C. Timmins Australia 15 80 0.4× 362 2.0× 137 0.9× 54 0.6× 14 0.2× 37 540
Sabrina Ramnarine United Kingdom 4 332 1.5× 886 4.9× 116 0.7× 108 1.2× 23 0.3× 9 1.1k
Stacey Bain United States 6 68 0.3× 371 2.0× 42 0.3× 80 0.9× 37 0.6× 7 477
Anthony M. Fletcher United States 10 105 0.5× 49 0.3× 53 0.3× 198 2.3× 43 0.7× 13 498
Edvina Galiè Italy 11 47 0.2× 184 1.0× 97 0.6× 88 1.0× 57 0.9× 26 576
Jing‐Dun Xie China 9 119 0.5× 160 0.9× 16 0.1× 153 1.8× 20 0.3× 10 360

Countries citing papers authored by Shoichi Ohwada

Since Specialization
Citations

This map shows the geographic impact of Shoichi Ohwada's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shoichi Ohwada with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shoichi Ohwada more than expected).

Fields of papers citing papers by Shoichi Ohwada

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shoichi Ohwada. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shoichi Ohwada. The network helps show where Shoichi Ohwada may publish in the future.

Co-authorship network of co-authors of Shoichi Ohwada

This figure shows the co-authorship network connecting the top 25 collaborators of Shoichi Ohwada. A scholar is included among the top collaborators of Shoichi Ohwada based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shoichi Ohwada. Shoichi Ohwada is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Goto, Kōichi, Yoshimasa Shiraishi, Haruyasu Murakami, et al.. (2023). Phase 1 study of DS‐1205c combined with gefitinib for EGFR mutation‐positive non‐small cell lung cancer. Cancer Medicine. 12(6). 7090–7104. 6 indexed citations
3.
Iwata, Hiroji, Ian E. Krop, Norikazu Masuda, et al.. (2023). PS2-4 Phase 1/2 study of HER3-DXd in HER3-expressing metastatic breast cancer: Subgroup analysis by HER2 expression. Annals of Oncology. 34. S1379–S1379. 2 indexed citations
4.
Krop, Ian E., Norikazu Masuda, Toru Mukohara, et al.. (2022). Results from the phase 1/2 study of patritumab deruxtecan, a HER3-directed antibody-drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC).. Journal of Clinical Oncology. 40(16_suppl). 1002–1002. 55 indexed citations
5.
Ohwada, Shoichi, et al.. (2021). Concentration–QTc analysis for single arm studies. Journal of Pharmacokinetics and Pharmacodynamics. 48(2). 203–211. 3 indexed citations
6.
Kato, Jitsu, et al.. (2021). Safety and Efficacy of Mirogabalin for Peripheral Neuropathic Pain: Pooled Analysis of Two Pivotal Phase III Studies. Clinical Therapeutics. 43(5). 822–835.e16. 19 indexed citations
7.
8.
Baba, Masayuki, et al.. (2020). Results of Mirogabalin Treatment for Diabetic Peripheral Neuropathic Pain in Asian Subjects: A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Study. SHILAP Revista de lepidopterología. 9(1). 261–278. 17 indexed citations
9.
Kato, Jitsu, et al.. (2020). Long-term safety and efficacy of mirogabalin in Asian patients with postherpetic neuralgia. Medicine. 99(36). e21976–e21976. 19 indexed citations
10.
Takahashi, Takeshi, Kensuke Usuki, Kosei Matsue, et al.. (2019). Efficacy and safety of quizartinib in Japanese patients with FLT3-ITD positive relapsed or refractory acute myeloid leukemia in an open-label, phase 2 study. International Journal of Hematology. 110(6). 665–674. 14 indexed citations
11.
Usuki, Kensuke, Hiroshi Handa, Ilseung Choi, et al.. (2019). Safety and pharmacokinetics of quizartinib in Japanese patients with relapsed or refractory acute myeloid leukemia in a phase 1 study. International Journal of Hematology. 110(6). 654–664. 17 indexed citations
12.
13.
Baba, Masayuki, et al.. (2019). Long‐term safety and efficacy of mirogabalin in Asian patients with diabetic peripheral neuropathic pain. Journal of Diabetes Investigation. 11(3). 693–698. 22 indexed citations
14.
Baba, Masayuki, et al.. (2019). Mirogabalin for the treatment of diabetic peripheral neuropathic pain: A randomized, double‐blind, placebo‐controlled phase III study in Asian patients. Journal of Diabetes Investigation. 10(5). 1299–1306. 84 indexed citations
15.
Jansen, Mendel, Steve Warrington, Victor Dishy, et al.. (2018). A Randomized, Placebo‐Controlled, Double‐Blind Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Repeated Doses of Mirogabalin in Healthy Asian Volunteers. Clinical Pharmacology in Drug Development. 7(6). 661–669. 20 indexed citations
16.
Brown, Karen, Jeanne Mendell, Shoichi Ohwada, et al.. (2018). Tolerability, pharmacokinetics, and pharmacodynamics of mirogabalin in healthy subjects: Results from phase 1 studies. Pharmacology Research & Perspectives. 6(5). e00418–e00418. 23 indexed citations
17.
Shimizu, Toshio, Kimio Yonesaka, Hidetoshi Hayashi, et al.. (2017). Phase 1 study of new formulation of patritumab (U3-1287) Process 2, a fully human anti-HER3 monoclonal antibody in combination with erlotinib in Japanese patients with advanced non-small cell lung cancer. Cancer Chemotherapy and Pharmacology. 79(3). 489–495. 19 indexed citations
18.
Ohwada, Shoichi & Satoshi Morita. (2016). Bayesian adaptive patient enrollment restriction to identify a sensitive subpopulation using a continuous biomarker in a randomized phase 2 trial. Pharmaceutical Statistics. 15(5). 420–429. 9 indexed citations
19.
Mukai, Hirofumi, Toshiaki Saeki, Kenjiro Aogi, et al.. (2016). Patritumab plus trastuzumab and paclitaxel in human epidermal growth factor receptor 2‐overexpressing metastatic breast cancer. Cancer Science. 107(10). 1465–1470. 31 indexed citations
20.
Saeki, Toshiaki, Hirofumi Mukai, Kenjiro Aogi, et al.. (2015). Phase I study of HER3 targeted antibody patritumab in combination with trastuzumab and paclitaxel in patients with HER2-overexpressing metastatic breast cancer (MBC).. Journal of Clinical Oncology. 33(15_suppl). 584–584. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kiyonori Kai Breakdown of academic impact, for papers by Ching Hsu Breakdown of academic impact, for papers by Tiffany Li Breakdown of academic impact, for papers by Marc Hattenberger Breakdown of academic impact, for papers by Hannah C. Timmins Breakdown of academic impact, for papers by Sabrina Ramnarine Breakdown of academic impact, for papers by Stacey Bain Breakdown of academic impact, for papers by Anthony M. Fletcher Breakdown of academic impact, for papers by Edvina Galiè Breakdown of academic impact, for papers by Jing‐Dun Xie
Rankless by CCL
2026